Compare Panacea Biotech with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DIVIS LABORATORIES - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DIVIS LABORATORIES PANACEA BIOTECH/
DIVIS LABORATORIES
 
P/E (TTM) x 9.9 35.7 27.8% View Chart
P/BV x 2.1 6.6 31.6% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PANACEA BIOTECH   DIVIS LABORATORIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
DIVIS LABORATORIES
Mar-19
PANACEA BIOTECH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3541,639 21.6%   
Low Rs1381,115 12.4%   
Sales per share (Unadj.) Rs74.6186.3 40.0%  
Earnings per share (Unadj.) Rs6.751.0 13.1%  
Cash flow per share (Unadj.) Rs15.557.3 27.0%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs57.2261.8 21.9%  
Shares outstanding (eoy) m61.25265.47 23.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.37.4 44.6%   
Avg P/E ratio x36.827.0 136.2%  
P/CF ratio (eoy) x15.924.0 66.0%  
Price / Book Value ratio x4.35.3 81.7%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m15,061365,592 4.1%   
No. of employees `0002.311.8 19.5%   
Total wages/salary Rs m1,4715,423 27.1%   
Avg. sales/employee Rs Th1,973.64,175.1 47.3%   
Avg. wages/employee Rs Th635.6457.7 138.9%   
Avg. net profit/employee Rs Th176.81,141.8 15.5%   
INCOME DATA
Net Sales Rs m4,56749,463 9.2%  
Other income Rs m451,556 2.9%   
Total revenues Rs m4,61251,019 9.0%   
Gross profit Rs m2,03018,718 10.8%  
Depreciation Rs m5401,689 32.0%   
Interest Rs m1,04835 2,995.1%   
Profit before tax Rs m48618,551 2.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m775,023 1.5%   
Profit after tax Rs m40913,527 3.0%  
Gross profit margin %44.437.8 117.4%  
Effective tax rate %15.927.1 58.6%   
Net profit margin %9.027.3 32.8%  
BALANCE SHEET DATA
Current assets Rs m2,41546,501 5.2%   
Current liabilities Rs m9,0778,468 107.2%   
Net working cap to sales %-145.976.9 -189.7%  
Current ratio x0.35.5 4.8%  
Inventory Days Days65131 49.8%  
Debtors Days Days7186 82.6%  
Net fixed assets Rs m8,33325,797 32.3%   
Share capital Rs m61531 11.5%   
"Free" reserves Rs m3,44368,962 5.0%   
Net worth Rs m3,50469,493 5.0%   
Long term debt Rs m4610-   
Total assets Rs m13,75580,383 17.1%  
Interest coverage x1.5531.0 0.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.30.6 54.0%   
Return on assets %10.616.9 62.8%  
Return on equity %11.719.5 60.0%  
Return on capital %38.726.7 144.7%  
Exports to sales %20.90-   
Imports to sales %8.124.6 33.1%   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m37212,187 3.1%   
Fx inflow Rs m1,20341,238 2.9%   
Fx outflow Rs m46712,405 3.8%   
Net fx Rs m73628,833 2.6%   
CASH FLOW
From Operations Rs m1,0499,543 11.0%  
From Investments Rs m-54-6,854 0.8%  
From Financial Activity Rs m-1,011-2,459 41.1%  
Net Cashflow Rs m-20230 -8.6%  

Share Holding

Indian Promoters % 74.5 52.0 143.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.8 5.1%  
FIIs % 1.3 19.0 6.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.2 137.2%  
Shareholders   10,259 31,796 32.3%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  AUROBINDO PHARMA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 15, 2019 03:37 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS